Hologic said on 19 October 2026 that it had signed a definitive agreement to acquire Reveal Genomics, a Barcelona precision oncology company. Terms were not disclosed.
Why Hologic, Inc. is buying Reveal Genomics, S.L.
Reveal's HER2DX test helps clinicians choose therapy for HER2-positive breast cancer, and TNBCDX targets triple-negative disease. Hologic said the tests are highly complementary to its Breast Cancer Index, a guideline-recognised assay for decisions on extended endocrine therapy.
Deal terms and financing
Neither company disclosed financial terms.
Regulatory approvals and timing
Completion depends on Spanish regulatory approval and other customary closing conditions.
Market context
Reveal Genomics was co-founded by chief executive Patricia Villagrasa-Gonzalez and has marketed HER2DX since 2022. The deal is part of a trend of diagnostics companies pairing cancer testing with treatment selection.
